EMA starts review of Immunome’s varegacestat application for desmoid tumors
+1 new source since this summary was written
On October 30, Immunome said the European Medicines Agency had completed its completeness check of the company’s varegacestat application, allowing centralized review to begin. The filing concerns an investigational once-daily oral gamma secretase inhibitor for adults with desmoid tumors. It is supported by Phase 3 RINGSIDE results, including an 84% reduction in progression or mortality events versus placebo, a 56% objective response rate versus 9%, and a hazard ratio of 0.16 with p<0.0001.
Why it matters
EMA validation moves varegacestat into the formal European review process but is not an authorization. Immunome’s U.S. application has already been accepted, with an FDA target action date of April 28, 2027, so the drug now has active regulatory pathways in both regions.
Key facts
- 1The EMA determined that Immunome’s application was complete and will begin its centralized assessment. investing.com
- 2The Phase 3 RINGSIDE study enrolled 156 patients receiving varegacestat 1.2 mg daily or placebo. finanznachrichten.de
- 3RINGSIDE showed an 84% lower likelihood of a progression or mortality event with varegacestat, with a hazard ratio of 0.16 and p<0.0001. stocktitan.net
- 4The objective response rate was 56% for varegacestat compared with 9% for placebo. investing.com
- 5The FDA accepted Immunome’s NDA in July 2026 and set April 28, 2027 as its PDUFA target action date. finanznachrichten.de
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.